Montserrat Pazos

Montserrat Pazos

Auto-generated profile, based on publicly available information

Montserrat Pazos

Department of Radiation Oncology, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
BHBianca A.W. Hoeben
Bianca A.W. Hoeben
MPMontserrat Pazos
Montserrat Pazos
MAMichael H. Albert
Michael H. Albert
ESEnrica Seravalli
Enrica Seravalli
MBMirjam E. Bosman
Mirjam E. Bosman
GJGeert O. Janssens
Geert O. Janssens
To reduce relapse risk, Total Body Irradiation (TBI) is part of conditioning regimens for hematopoietic stem cell transplantation (HSCT) in pediatric acute leukemia. The study purpose was to evaluate clinical practices regarding TBI, such as fractionation, organ shielding and delivery techniques, among SIOPE affiliated radiotherapy centers. An electronic survey was sent out to 233 SIOPE affiliated centers, containing 57 questions about clinical practice of TBI. Surveys could be answered anonymously. From over 25 countries, 82 responses were collected. For TBI-performing centers, 40/48 irradiated ≤10 pediatric patients annually (range: 1-2 to >25). Most indications concerned acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Four different fractionation schedules were used, of which 12 Gy in 6 fractions was applied in 91% for ALL and 86% for AML. Dose reduction to the lungs, mostly to a mean dose of 8-10 Gy, was applied by 28/33 centers for ALL and 19/21 centers for AML, in contrast to much less applied dose reduction to the kidneys (7/33 ALL and 7/21 AML), thyroid (2/33 ALL and 2/21 AML), liver (4/33 ALL and 3/21 AML) and lenses (4/33 ALL and 4/21 AML). Conventional TBI techniques were used by 24/29 responding centers, while 5/29 used advanced optimized planning techniques. Across SIOPE, there is a high level of uniformity in fractionation and use of lung shielding. Practices vary regarding other organs-at-risk shielding and implementation of advanced techniques. A SIOPE radiotherapy working group will be established to define international guidelines for pediatric TBI.

3 December 2024 in ESMO Open
Verified
Journal Article
Open access
SSS. Schönecker
S. Schönecker
LALucia Angelini
Lucia Angelini
AGA. Gaasch
A. Gaasch
AZA. Zinn
A. Zinn
DKD. Konnerth
D. Konnerth
SCStefanie Corradini
Stefanie Corradini
Adjuvant radiotherapy (RT) plays an essential role in the management of early breast cancer (BC), but can lead to cardiovascular and lung toxicities. RT in deep inspiration breath hold (DIBH) often allows better protection of organs at risk. This prospective study compares surface-guided DIBH with free breathing (FB) in patients with left-sided BC, by evaluating individual cardiovascular risks and treatment plan dosimetry. The study enrolled 585 patients from October 2016 to January 2021 with left-sided invasive breast carcinoma with indicated adjuvant RT of the breast/thoracic wall with or without regional lymph nodes. The ability to hold breath for 20 s was a prerequisite. The treatments were either hypofractionated (HF; 40.05 Gy/15Fx) or normofractionated (NF; 50.00 Gy/25Fx). DIBH was applied using the automatically triggered surface guidance system Catalyst with audio-video feedback. Computed tomography and surface data were acquired during both DIBH and FB. The primary endpoint of the study was the comparative evaluation of heart dose reduction using DIBH. Plan dosimetry was significantly improved by DIBH. The mean and maximum doses to the heart and the left coronary artery were significantly reduced by 36%-42% in HF and NF plans (P < 0.001), while the mean ipsilateral lung dose was reduced by 12%-14% (P < 0.001). Furthermore, DIBH resulted in a 5% reduction in the cumulative 10-year cardiovascular disease risk (10-year cardiovascular disease risk) compared with FB (3.59% to 3.41%; P < 0.001). To the best of our knowledge, this is the largest prospective study showing better sparing for cardiac and ipsilateral lung doses with surface-guided DIBH compared with FB in patients with left-sided BC.

16 July 2020 in Geburtshilfe und Frauenheilkunde
Verified
Conference Paper
Closed access
SCS Corradini
S Corradini
MPM Pazos
M Pazos
SSSonja Schönecker
Sonja Schönecker
DRD Reitz
D Reitz
MNMaximilian Niyazi
Maximilian Niyazi
CBC Belka
C Belka
Fragestellung Die Behandlung von älteren Patientinnen mit Brustkrebs weicht im klinischen Alltag häufig von den interdisziplinären Therapieempfehlungen ab. Ziel der vorliegenden Studie war es, die Versorgungsrealität und das onkologische Ergebnis der Strahlentherapie (RT) bei älteren Patientinnen zu evaluieren, welche in einem modernen klinischen Umfeld außerhalb von klinischen Studien behandelt wurden. Methoden Es wurden Patientinnen mit der Diagnose Brustkrebs und einem Alter >65 Jahre ausgewertet, welche zwischen 1998-2014 an zwei großen Brustzentren behandelt wurden. Ergebnisse Die endgültige Studienkohorte bestand aus 4469 Frauen mit einem medianen Follow-up von 90,8 Monaten. Insgesamt erhielten 26,2 % der Patientinnen eine Mastektomie, 71,0 % eine brusterhaltende OP und 2,8 % wurden nicht operiert. Durch die adjuvante RT konnte eine signifikante Verbesserung der lokoregionären Tumorkontrolle nach BEO erreicht werden (p < 0,001). Auch in der multivariaten Analyse zeigte sich hierbei ein Vorteil durch die RT (HR:3,121;95 %KI:2,239-4,352;p < 0,001), während dies in der Mastektomie-Gruppe nicht signifikant war. Außerdem konnte durch die RT das 10-Jahres Risiko für Fernmetastasen signifikant reduziert werden (HR: 1,667; 95 %CI:1,320-2,106, p < 0,001), was mit einem verbesserten Gesamtüberleben assoziiert war (HR:1,630; 95 %KI:1,376-1,932; p < 0,001). In der Mastektomie-Gruppe wies die Hochrisikogruppe der bestrahlten Patientinnen hingegen häufiger Fernmetastasen auf (p < 0,001). Bei Low-risk-Patientinnen (BEO,pT1pN0/pT2pN0,R0,Hormonrezeptor-positiv,Her2neu-negativ) führte die RT zu einer signifikanten Verbesserung der lokoregionären Tumorkontrolle (p < 0,001), auch wenn eine endokrine Therapie durchgeführt wurde (p < 0,001). Schlussfolgerungen Zusammenfassend bestätigt diese Arbeit die Effektivität der postoperativen Strahlentherapie bei älteren Patientinnen (>65 Jahre). Die Indikation zur adjuvanten Radiotherapie sollte für das Kollektiv älterer Patientinnen -nach einer individuellen Abwägung der Lebenserwartung- konsequent gestellt werden, um eine Untertherapie dieser Patientinnen zu verhindern. Article published online: 16 July 2020 © Georg Thieme Verlag KG Stuttgart · New York

26 May 2026 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
SMSebastian Hubertus Maier
Sebastian Hubertus Maier
ANAlexander Nitschmann
Alexander Nitschmann
DDDiana-Coralia Dehelean
Diana-Coralia Dehelean
LHLea Horne
Lea Horne
CBCecile Baumgartner
Cecile Baumgartner
SSStephan Schönecker
Stephan Schönecker
Brain metastases (BM) occur in up to 40% of patients with solid tumors. Following surgical resection, postoperative radiotherapy to the resection cavity is standard of care, yet optimal dose prescription and fractionation remain uncertain. This study evaluates clinical outcomes and toxicity of a standardized postoperative fractionated stereotactic radiotherapy (fSRT) regimen. This retrospective single-center study included patients treated between 2017 and 2025 with postoperative fSRT for completely resected brain metastases. All patients received 25 Gy in five fractions, prescribed to the 80% isodose line. The planning target volume (PTV) was defined as the resection cavity plus a 2-mm margin. Primary endpoints were local control (LC) and symptomatic radiation necrosis. Secondary endpoints included overall survival (OS) and intracranial progression-free survival (iPFS). Survival outcomes were estimated using the Kaplan-Meier method, and Cox regression analyses were performed to identify prognostic factors. A total of 159 patients and 181 resection cavities were analyzed. The median PTV was 22.3 cc, while the median clinical target volume (CTV) measured 13.8 cc. Median follow-up was 48 months. Local control rates at 12 and 48 months were 91.8% and 89.4%, respectively. Symptomatic radiation necrosis occurred in 3.2% of patients. Median OS was 31 months, and median iPFS was 20 months. In multivariable analysis, uncontrolled extracranial disease was the only independent predictor of inferior OS (hazard ratio 2.58, p < 0.001). Postoperative fSRT with 5 × 5 Gy prescribed to the 80% isodose line is safe, well-tolerated, and provides durable local control after surgical tumor removal. Additional evidence is eagerly anticipated from the ongoing phase 3 trials. The local ethical review committee of Ludwig-Maximilians-University Munich (application number: 24–0206) approved this study. The study has been officially registered on the German Clinical Trials Register (DRKS00034150) on December 20, 2024.